Hepatitis C virus (HCV) is a major public health problem and is considered the most common etiology of chronic liver disease in Egypt. Many studies were conducted to find accurate prediction of response prior to initiation of therapy. Pretreatment serum Interferon γ inducible protein 10 (IP-10) is an independent predictive factor of SVR in HCV patients infected by genotype 1. Aim of work: To prove whether IP-10 can be used as a predictor of response to treatment of chronic HCV Egyptian patients.Patients and methods: The study was conducted on 88 patients with chronic HCV who received pegylated interferon & ribavirin. All patients were subjected to pretreatment routine laboratory evaluation and pretreatment serum IP-10 assesssment. They were classified into 3 groups according to their response; NR or SVR. Comparison of pretreatment IP-10 with response and different parameters was done.Results: The mean of IP-10 in the whole studied group was 217.24 pg/ml with SD of 168.32. No significant correlation between the pretreatment IP-10 level and response was found when measured by median and IQR; at week 12 in EVR and NR, 172(201) and 174(288) respectively with P-value=0.58, at week 24 in responders and those who had breakthrough, 186(198) and 164(257) respectively with P-value=0.8, at end of treatment in responders and NR, 181(169) and 168(254) respectively with P-value=0.47, at week 72 in those who achieved SVR and those who failed treatment, 163(139) and 179(245) respectively with P-value=0.43. IP-10 was compared to inflammatory activity and fibrosis in the studied groups and was found to be non-significant with P-values= 0.94 and 0.86 respectively.Conclusion: Pretreatment IP-10 can’t be used as a predictor of response to combination therapy in chronic HCV Egyptian patients.